Skip to content

Addiction: all studies

Page 622 of 863: studies 6,211 to 6,220 of 8,627, newest first. Back to the addiction overview

Research

Consciousness at the Interface: Wendt, Eastern Wisdom and the Ethics of Intra-Action

Critical Review April 3, 2017 K. M. Fierke 20 citations

Drawing on the family resemblance between quantum physics and Eastern wisdom identified by Niels Bohr, this article brings insights from Buddhism and Daoism to the task of enhancing our understanding of the significance of Alexander Wendt’s argument for a quantum-based social science. Five areas of overlap between his argument and Eastern wisdom are explored: vitalism and the idea that life...

Ketamine and electroconvulsive therapy pairing in depression and mood disorders

April 3, 2017 S. Kose, M. Çetin

Although a number of medications are available for treatment of depressive disorders, one of the major limitations of all present antidepressants is delayed onset of action [1]. In addition, despite recent advances in the pharmacological and non-pharmacological treatment of major depressive disorder, almost one third of patients fail to respond to any treatments [2]. In recent years, one of the...

Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.

Neuroscience & Biobehavioral Reviews April 2017 Justine Renard, Christopher Norris, Walter J Rushlow et al.

Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of cannabis, as a potential pharmacotherapy for various neuropsychiatric disorders. In contrast to delta-9-tetrahydrocannabinol (THC), which is associated with acute and neurodevelopmental pro-psychotic side-effects, CBD possesses no known psychoactive or...

NMDA receptor adjusted co-administration of ecstasy and cannabinoid receptor-1 agonist in the amygdala via stimulation of BDNF/Trk-B/CREB pathway in adult male rats.

Brain Research Bulletin April 2017 Ghorbangol Ashabi, Mitra-Sadat Sadat-Shirazi, Solmaz Khalifeh et al.

Consumption of cannabinoid receptor-1 (CB-1) agonist such as cannabis is widely taken in 3,4- methylenedioxymethamphetamine (MDMA) or ecstasy users; it has been hypothesized that co-consumption of CB-1 agonist might protect neurons against MDMA toxicity. N-methyl-d-aspartate (NMDA) receptors regulate neuronal plasticity and firing rate in the brain through Tyrosine-kinase B (Trk-B) activation....

Effects of serotonergic hallucinogen R (−)‐2,5‐Dimethoxy‐4‐iodoamphetamine (DOI) on temporal discrimination in mice

The FASEB Journal April 1, 2017 Michael P Trahan, Sebastian Leth-Petersen, William E Fantegrossi

R (−)‐2,5‐Dimethoxy‐4‐iodoamphetamine (DOI) and other compounds with agonist affinity for serotonergic 5‐HT2A receptors are hallucinogenic drugs of abuse, but also have therapeutic potential in numerous neuropsychiatric conditions, including major depressive disorder, post‐traumatic stress disorder, and in the treatment of migraine and cluster headaches. Thus, commonly abused hallucinogens...

Psychosis – Different presentation for designer drugs compared to cannabis abusers?

European Psychiatry April 1, 2017 F. Dumitrescu

Introduction: “Bath salts” target the endocannabinoid system in a similar manner to cannabis. In the case of designer drug misuse, subjects seem to be at higher risk of psychotic symptoms. Aims: To investigate the nature and frequency of psychotic symptoms associated with cannabis and/or bath salts misuse in a male inpatient population. Method: The files of 107 patients admitted to the...

Clinical predictors of antidepressant response to ketamine in unipolar treatment-resistant depression

European Psychiatry April 1, 2017 L.C. Del Sant, E. Magalhães, Ana C. Lucchese et al.

Introduction: The non-competitive N-methyl-d-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in treatment-resistant depression (TRD). However, only a few studies have investigated which clinical characteristics predict a response to ketamine. Objectives: To assess sociodemographic variables and clinical markers that predict response to...

Ketamine-dependent neuronal activation in healthy volunteers.

Brain Structure and Function April 2017 Anna S. Höflich, Andreas Hahn, Martin Küblböck et al.

Over the last years, a number of studies have been conducted to clarify the neurobiological correlates of ketamine application. However, comprehensive information regarding the influence of ketamine on cortical activity is still lacking. Using resting-state functional MRI and integrating pharmacokinetic information, a double-blind, randomized, placebo-controlled, crossover study was performed...

Comparative examination of the differences between cannabis psychosis and methamphetamine psychosis in a psychological state

European Psychiatry April 1, 2017 A. Oda

BackgroundWith the rapid and intensive spread of marihuana abuse among youth, Japanese society is focusing on law enforcement against drug abusers. In 2016, a mass killing allegedly committed by a marihuana abuser was reported in Japan.ObjectivesTo consider that common recognition of the diverse process and potential risks of cannabis psychosis should be shared among psychiatrists.AimsElicit...

Elucidating Functional Selectivity at the 5‐HT 2A Receptor

The FASEB Journal April 1, 2017 Gerald Billac, Charles D. Nichols

There has been a recent resurgence of clinical interest in the application of psychedelic drugs for the treatment of various disease states. While the field is mostly focused on action within the central nervous system, previously published data from our lab supports the use of these 5‐hydroxytryptamine 2A receptor (5‐HT 2A R) agonists as modulators of the inflammatory pathway in the periphery...

DOI: 10.1096/fasebj.31.1_supplement.663.2 (opens in new tab) Serotonin Arrestin 5-HT Receptor Functional selectivity +13